JP Morgan Chase’s RAPT Therapeutics RAPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-1,668
| Closed | -$56.5K | – | 7824 |
|
|
2025
Q4 | $56.5K | Buy |
1,668
+1,345
| +416% | +$41.8K | ﹤0.01% | 6177 |
|
|
2025
Q3 | $8.33K | Sell |
323
-1
| -0.3% | -$13 | ﹤0.01% | 6686 |
|
|
2025
Q2 | $2.59K | Sell |
324
-13,217
| -98% | -$101K | ﹤0.01% | 6502 |
|
|
2025
Q1 | $132K | Sell |
13,541
-12,105
| -47% | -$119K | ﹤0.01% | 5432 |
|
|
2024
Q4 | $324K | Buy |
25,646
+23,558
| +1,128% | +$299K | ﹤0.01% | 5263 |
|
|
2024
Q3 | $33.6K | Buy |
2,088
+16
| +0.8% | +$324 | ﹤0.01% | 6110 |
|
|
2024
Q2 | $50.5K | Sell |
2,072
-359
| -15% | -$16.6K | ﹤0.01% | 5856 |
|
|
2024
Q1 | $175K | Sell |
2,431
-848
| -26% | -$118K | ﹤0.01% | 5413 |
|
|
2023
Q4 | $652K | Sell |
3,279
-21
| -0.6% | -$2.6K | ﹤0.01% | 4621 |
|
|
2023
Q3 | $439K | Buy |
3,300
+248
| +8% | +$40.5K | ﹤0.01% | 4560 |
|
|
2023
Q2 | $457K | Sell |
3,052
-22
| -0.7% | -$3.43K | ﹤0.01% | 4544 |
|
|
2023
Q1 | $451K | Buy |
3,074
+1,013
| +49% | +$205K | ﹤0.01% | 4575 |
|
|
2022
Q4 | $326K | Buy |
2,061
+9
| +0.4% | +$1.44K | ﹤0.01% | 4776 |
|
|
2022
Q3 | $395K | Buy |
2,052
+118
| +6% | +$22.3K | ﹤0.01% | 4603 |
|
|
2022
Q2 | $283K | Buy |
1,934
+237
| +14% | +$31.6K | ﹤0.01% | 4895 |
|
|
2022
Q1 | $299K | Buy |
1,697
+325
| +24% | +$61.4K | ﹤0.01% | 4974 |
|
|
2021
Q4 | $403K | Sell |
1,372
-888
| -39% | -$237K | ﹤0.01% | 4967 |
|
|
2021
Q3 | $561K | Buy |
2,260
+1,240
| +122% | +$328K | ﹤0.01% | 4658 |
|
|
2021
Q2 | $259K | Buy |
1,020
+497
| +95% | +$92.9K | ﹤0.01% | 5095 |
|
|
2021
Q1 | $93K | Sell |
523
-1,065
| -67% | -$176K | ﹤0.01% | 5390 |
|
|
2020
Q4 | $251K | Buy |
1,588
+559
| +54% | +$122K | ﹤0.01% | 4727 |
|
|
2020
Q3 | $226K | Sell |
1,029
-2,545
| -71% | -$565K | ﹤0.01% | 4304 |
|
|
2020
Q2 | $830K | Buy |
3,574
+3,512
| +5,665% | +$543K | ﹤0.01% | 3615 |
|
|
2020
Q1 | $11K | Sell |
62
-1
| -2% | -$228 | ﹤0.01% | 5039 |
|
|
2019
Q4 | $14K | Buy |
+63
| New | +$11.6K | ﹤0.01% | 5357 |
|
JP Morgan Chase's RAPT Position: Q1 2026 in Review
JP Morgan Chase sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 1,668 shares — an estimated $56.5K sold.
JP Morgan Chase first reported a position in RAPT in Q4 2019 and held it in 25 quarters. The position peaked at $830K in Q2 2020. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.
- JP Morgan Chase reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
- JP Morgan Chase sold 1,668 RAPT Therapeutics shares in Q1 2026, an estimated $56.5K.
- JP Morgan Chase first reported a position in RAPT Therapeutics in Q4 2019 and held it in 25 quarters.
- JP Morgan Chase's RAPT Therapeutics position peaked at $830K in Q2 2020.
- 0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.